Exposures to 1,3-dimethylamylamine-containing products reported to Texas poison centers

Hum Exp Toxicol. 2013 Jan;32(1):18-23. doi: 10.1177/0960327112454895. Epub 2012 Oct 11.

Abstract

1,3-Dimethylamylamine (DMAA) is an ingredient in a number of weight loss and exercise performance enhancing products. However, information on the safety of DMAA-containing products is limited. Exposures to DMAA-containing products reported to Texas poison centers during 2010-2011 were identified and selected factors were examined. A total of 56 exposures were found, of which 75.0% were reported during 2011. OxyElite Pro™ was the reported product in 80.4% of the exposures. The patients were 51.8% male and 55.4% age ≤5 years. The patient was managed on site (such as at home) in 57.1% of the cases, and the exposure was known or expected to result in an outcome that was classified as not serious in 80.4%. The most frequently reported clinical effects were tachycardia (28.6%), nausea (16.1%), and vomiting (12.5%). The most common treatments were dilution (41.1%), food (19.6%), and activated charcoal (14.3%). It should be noted that the adverse clinical effects may be due to other ingredients in the DMAA-containing products, such as caffeine.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Amines / adverse effects*
  • Child
  • Child, Preschool
  • Dietary Supplements / adverse effects*
  • Female
  • Humans
  • Infant
  • Male
  • Nausea / chemically induced
  • Poison Control Centers / statistics & numerical data*
  • Tachycardia / chemically induced
  • Texas
  • Vomiting / chemically induced
  • Young Adult

Substances

  • 1,3-dimethylamylamine
  • Amines